D-Index & Metrics Best Publications

Michael E. Weinblatt

Brigham and Women's Hospital
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 101 Citations 55,761 521 World Ranking 4617 National Ranking 2577

Overview

What is he best known for?

The fields of study Michael E. Weinblatt is best known for:

Inflammation
Arachidonic acid
Rituximab

Michael E. Weinblatt regularly links together related areas like Calcium in his Internal medicine studies. His study ties his expertise on Internal medicine together with the subject of Calcium. In his articles, Michael E. Weinblatt combines various disciplines, including Rheumatoid arthritis and Rituximab. Rituximab and Rheumatoid arthritis are two areas of study in which he engages in interdisciplinary work. His research on Pathology often connects related areas such as Randomized controlled trial. As part of his studies on Randomized controlled trial, Michael E. Weinblatt often connects relevant areas like Pathology. Michael E. Weinblatt integrates many fields in his works, including Placebo and Alternative medicine. Michael E. Weinblatt integrates Alternative medicine and Adverse effect in his research. He combines Adverse effect and Placebo in his research.

His most cited work include:

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study (346 citations)
Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis (198 citations)

What are the main themes of his work throughout his whole career to date

His Renal function research covers fields of interest such as Renal blood flow and Creatinine. He performs integrative Creatinine and Renal function research in his work. Rheumatoid arthritis and Certolizumab pegol are frequently intertwined in his study. In his works, he performs multidisciplinary study on Certolizumab pegol and Adalimumab. He performs multidisciplinary study in the fields of Adalimumab and Golimumab via his papers. Michael E. Weinblatt merges Golimumab with Methotrexate in his research. He performs multidisciplinary study in the fields of Methotrexate and Rituximab via his papers. His multidisciplinary approach integrates Rituximab and Rheumatoid arthritis in his work. In his works, he conducts interdisciplinary research on Internal medicine and Family medicine.

Michael E. Weinblatt most often published in these fields:

Rheumatoid arthritis (91.67%)
Internal medicine (91.67%)
Pathology (41.67%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Principal components analysis corrects for stratification in genome-wide association studies

Alkes L Price;Alkes L Price;Nick J Patterson;Robert M Plenge;Robert M Plenge;Michael E Weinblatt.
Nature Genetics (2006)

9857 Citations

American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

David T. Felson;David T. Felson;Jennifer J. Anderson;Jennifer J. Anderson;Maarten Boers;Claire Bombardier;Claire Bombardier.
Arthritis & Rheumatism (1995)

3323 Citations

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Michael E. Weinblatt;Joel M. Kremer;Arthur D. Bankhurst;Ken J. Bulpitt.
The New England Journal of Medicine (1999)

2654 Citations

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Michael E. Weinblatt;Edward C. Keystone;Daniel E. Furst;Larry W. Moreland.
Arthritis & Rheumatism (2003)

2308 Citations

Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial

Larry W. Moreland;Michael H. Schiff;Scott W. Baumgartner;Elizabeth A. Tindall.
Annals of Internal Medicine (1999)

1910 Citations

The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

Shixin Qin;James B. Rottman;Paul Myers;Nasim Kassam.
Journal of Clinical Investigation (1998)

1644 Citations

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie.
Nature Genetics (2010)

1432 Citations

Efficacy of low-dose methotrexate in rheumatoid arthritis.

Michael E. Weinblatt;Jonathan S. Coblyn;David A. Fox;Patricia A. Fraser.
The New England Journal of Medicine (1985)

1180 Citations

Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production

Eric Boilard;Peter A. Nigrovic;Peter A. Nigrovic;Katherine Larabee;Gerald F. M. Watts.
Science (2010)

1143 Citations

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Stanley Cohen;Eric Hurd;John Cush;Michael Schiff.
Arthritis & Rheumatism (2002)

905 Citations

If you think any of the details on this page are incorrect, let us know.